Form 4: United Therapeutics CEO Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4
Martine Rothblatt, CEO of United Therapeutics, executed stock option exercises and sales on April 3rd and 4th, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics Corp, executed transactions involving common stock on April 3rd and 4th, 2024.
- These transactions involved the exercise of stock options and subsequent sale of common stock.
- The exercises and sales were conducted under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both April 3rd and 4th, 15,000 stock options were exercised at a price of $129.49 per share.
- Following the exercise of options on April 3rd, a total of 15,723 shares were sold at weighted average prices ranging from $223.73 to $231.69.
- Following the exercise of options on April 4th, a total of 15,000 shares were sold at weighted average prices ranging from $230.65 to $234.63.
- After these transactions, Rothblatt directly owns 130 shares of common stock.
- Rothblatt also directly owns 387,529 stock options.
- The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 5
Explanation: The filing is a standard disclosure of insider trading activity under a pre-arranged plan, indicating a neutral sentiment.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Industry Context
This filing is a routine disclosure of insider transactions, which are common among publicly traded companies. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any inside information at the time of the trades.
Comparison to Industry Standards
- Executive compensation packages often include stock options as a form of long-term incentive.
- The use of 10b5-1 trading plans is a standard practice for corporate insiders to manage their stock holdings while avoiding accusations of insider trading.
- Comparable companies in the biotechnology sector, such as Amgen, Gilead Sciences, and Biogen, also have executives who utilize similar trading plans.
Key Dates
| Date | Description |
|---|---|
| 2014-12-31 | Original exercisable date of stock options |
| 2023-08-04 | Date of establishment of the 10b5-1 trading plan |
| 2024-04-03 | Date of first stock option exercise and sale |
| 2024-04-04 | Date of second stock option exercise and sale |
| 2024-04-05 | Date of filing |
| 2024-08-31 | Potential end date of the 10b5-1 trading plan |
| 2024-12-31 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.